Login to Your Account

Pre-NDA meeting seemed to go well, but . . .
After what Amicus Therapeutics Inc. characterized last month as an upbeat NDA meeting, U.S. regulators have sent word that the package for migalastat, its oral small-molecule pharmacological chaperone to treat the alpha-galactosidase A shortage in Fabry disease, needs to include more. more »

Our Habitat for All Things Science
Vaccines are bright spot in infectious disease fight

SAN DIEGO – Predictions at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting tend to be of the dire sort, warning of a return to the pre-penicillin era. So it was a pleasant exception to listen to Glaxosmithkline plc's Rino Rappuoli brim with optimism during his plenary talk on challenges and opportunities of vaccines.



Partners in Focus